Treatment of Preseptal Cellulitis

Initial Assessment and Management

For mild preseptal cellulitis with less than 50% eyelid closure, the American Academy of Pediatrics recommends treatment as an outpatient with high-dose amoxicillin-clavulanate for comprehensive coverage of streptococci, staphylococci, and anaerobes, with mandatory daily follow-up until definite improvement is noted 1
The American Academy of Pediatrics suggests that eyelid involvement severity should be measured, and if less than 50% closed, outpatient management is appropriate 1
The presence of orbital signs, such as proptosis, impaired visual acuity, or painful/impaired extraocular movements, indicates progression to orbital cellulitis requiring immediate hospitalization, as recommended by the American Academy of Pediatrics 1

The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate (Augmentin 875/125 mg twice daily in adults; weight-based dosing in children) as first-line therapy for mild cases, providing comprehensive coverage for streptococci, staphylococci, and anaerobes 1, 2
Alternative oral agents, such as cephalexin 500 mg four times daily, dicloxacillin, or clindamycin, can be used for penicillin-allergic patients, as suggested by the Infectious Diseases Society of America 2, 3

The Infectious Diseases Society of America notes that MRSA coverage is generally unnecessary for typical preseptal cellulitis, as beta-lactam therapy succeeds in 96% of cases 4, 2
Consider adding MRSA coverage with vancomycin (IV) or clindamycin (oral) in specific situations, such as penetrating trauma, history of injection drug use, purulent drainage, evidence of MRSA infection elsewhere, or failure of initial beta-lactam therapy, as recommended by the Infectious Diseases Society of America 2, 3, 4

The American Academy of Pediatrics recommends daily follow-up mandatory for patients treated as outpatients, with evaluation until definite improvement is documented 1
Escalation criteria, such as no improvement within 24-48 hours or infection progression, require admission for IV antibiotics, as suggested by the American Academy of Pediatrics 1

Immunocompromised patients, such as those with malignancy or severe immunodeficiency, are at higher risk for complications, including streptococcal toxic shock syndrome, and may require broader coverage and a lower threshold for hospitalization, as noted by the Infectious Diseases Society of America 4